Our Board of Directors

Juliet Thompson,

Non-Executive Chairman

Juliet Thompson joined the Company as Non-Executive Chairman on 25 April 2016.  She is also Chairman of the Nomination Committee and a member of the Audit and Remuneration Committees.

Juliet Thompson, a chartered accountant, is also a non-executive director of Nexstim Limited, a medical technology company quoted on Nasdaq in Finland and Sweden and was Vice President of Corporate Finance of Precision Ocular, a company focused on retinal diseases, for which she recently led a successful fundraising. Between 1995 and 2015, Juliet was a senior investment banker and built a strong track record advising healthcare corporates on strategy and the capital markets.  She formerly headed up the healthcare team at Stifel and founded Code Securities, a healthcare investment-banking boutique, which was sold to Nomura International.  At Nomura Code, she held the position of Head of Corporate Finance and served on the Board of Directors. 

Dominic Tonner,

Chief Executive Officer

Dominic Tonner was appointed as Chief Executive Officer on 27 February 2015. Prior to joining the Company he had been Chief Executive Officer of Premier Veterinary Group Limited since July 2007. During that time he had taken the revenues from £2 million to £7.5 million per annum, completed six acquisitions and integrated the activities successfully, launched a new business, Premier Veterinary Alliance, to become the second biggest buying group in the sector within three years. Mr Tonner began his career in 1979 at Lex Service Group plc after graduating from Strathclyde University with a BA in Politics & Sociology. He then went on to hold a number of posts in marketing within the transport industry before moving to Wiggin Teape where he was able to gain additional valuable European marketing experience. Following this he founded his own company within the label and barcode technology sector which was successfully sold to API Plc. In addition to building new revenue streams, Mr Tonner has been instrumental in raising capital and developing growth strategies.

Will Evans,

Chief Financial Officer

Will Evans was appointed as Chief Financial Officer on 19 September 2016.  Prior to joining the Company, Will held a number of senior management and finance positions in other UK listed companies.  From 2009 to 2015, he was at Tribal Group plc where he held roles as Group Financial Controller, Divisional Finance Director for Tribal’s Services Division and, most recently, as Corporate Development Director.   Prior to joining Tribal Group plc, he was Group Financial Controller at Synergy Health plc.  Will qualified as a chartered accountant with Arthur Andersen.

Raj Uppal,

Corporate Development Director

Raj Uppal was appointed as Corporate Development Director on 27 February 2015.

Mr Uppal is a Chartered Accountant with significant commercial and corporate finance experience and has served on the boards of several publicly quoted and private companies across various business sectors in both executive and non-executive roles. After qualifying as a Chartered Accountant in 1986 he began his career in industry in 1989 as the Chief Financial Officer of a fully quoted European printing and packaging group, Ferry Pickering Group plc. Following the successful disposal of that company Mr Uppal joined Quadrant Healthcare plc (“Quadrant”) as its Chief Financial Officer and was part of the team that floated Quadrant on the London Stock Exchange. At the time of Quadrant’s disposal to Elan Corporation plc (“Elan”) in 2000 Mr Uppal held the position of Finance and Commercial Director and was subsequently appointed as a Senior Vice President within Elan. Mr Uppal led the management buyout of various companies within Elan in 2003 and merged these companies with ML Laboratories plc in 2005 to create a new group, Innovata PLC, where he served as a Non-Executive Director until it was acquired by Vectura Group plc. Mr Uppal also served as a Non-Executive Director of Oxford BioMedica plc between 2001 and 2006.

Iain Ross,

Non-Executive Director

Iain Ross joined the Company as Executive Chairman on 9 September 2010.  Mr Ross has over 35 years’ experience in the international life sciences and technology sectors where he has completed multiple financing transactions, and over 25 years in cross-border management as a Chairman and CEO.  He has led and participated in five Initial Public Offerings, and has direct experience of M&A transactions in Europe, USA and Pacific Rim.

Currently he is Executive Chairman of e-Therapeutics plc (LSE: ETX) and non-Executive Chairman of Biomer Technology Ltd; and also a non-executive director of Anatara LifeSciences Ltd and Novogen Ltd, both of which are listed on the ASX.  He is a qualified Chartered Director, and Vice Chairman of the Council of Royal Holloway, London University.

Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc where, as CEO of Celltech Biologics plc, he moved the company from a loss-making position to reporting a net profit before the sale to Lonza. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the company public, signing numerous collaborations and selling the business to Elan in 2001. As Chairman and CEO at Allergy Therapeutics he re-structured the company balance sheet to position Allergy Therapeutics as a virtually debt-free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. He continues to consult for private equity groups on biotech and technology company turnarounds.

On 31 March 2013, the permanent position of Executive Chairman was made redundant.  Mr Ross was appointed as Non-Executive Chairman on 1 April 2013 and stepped down from that position on 25 April 2016, having overseen the successful reverse takeover of the Company into Ark Therapeutics Group plc in February 2015.  Mr Ross remains on the Board as a non-executive director and is also a member of the Nomination, Audit and Remuneration Committees.

Graham Dick BVSc MRCVS,

Non-Executive Director

Graham Dick BVSc MRCVS was appointed as a non-executive director on 9 March 2015.  He is also Senior Independent Director, Chairman of the Audit and Remuneration Committees and a member of the Nomination Committee.  A Bristol University graduate, Mr Dick spent 15 years in mixed veterinary practice, first in Somerset then as a partner in Norfolk, before a change of track led him to the world of animal therapeutics both in the UK and overseas with Bayer Animal Health. His overseas roles included that of Head of Marketing and Technical Service for Australia/New Zealand, Global Head of Livestock Business and Head of European Marketing before returning to the UK as Head of the Animal Health Division of Bayer for the UK and Ireland, from which he finally retired in 2013, having taken it to the best performing Bayer Animal Health subsidiary in Europe. He currently provides consultancy services to international veterinary businesses. 

Mr Dick served for 10 years on the Board of the National Office of Animal Health (NOAH), of which he was elected Chairman for a period of three years and is now an honorary life member for services to the animal health industry.  He currently serves on the Board of the Veterinary Charity “Vetlife” (formerly VBF), for which he is Treasurer and takes a special interest in CPD matters; he is also on the Board of RCVS Knowledge (Royal College of Veterinary Surgeons) and the Board of The WikiVet Trading Company Limited, the commercial arm of the WikiVet veterinary learning support project.

Keep Up-to-Date

Keep up-to-date with product developments, investor relations information and news with our email updates.

© Premier Veterinary Group plc - Registered No 04313987 - Registered in England and Wales

Delivered by Investis – link to website (opens in a new window)